News Agency
The Times

Turn Biotechnologies Signs Global Licensing Agreement with HanAll Biopharma to Develop Eye and Ear Therapies

  • Written by PR Newswire
Turn Biotechnologies Signs Global Licensing Agreement with HanAll Biopharma to Develop Eye and Ear Therapies
  • Synergistic collaboration to revolutionize age-related therapies worldwide
  • Deal valued at over $300 million USD for initial product

MOUNTAIN VIEW, Calif., May 28, 2024 /PRNewswire/ -- Turn Biotechnologies, a developer of novel mRNA medicines and enabling technologies, today announced an exclusive global licensing agreement with pharmaceutical...

Read more: Turn Biotechnologies Signs Global Licensing Agreement with HanAll Biopharma to Develop Eye and Ear...

How Can Businesses Reduce the Risk of Commercial Litigation?

Commercial disputes often begin with a misunderstanding, an unclear contract or a delayed response to a growing problem. Seeking early advice from Litigation Lawyers Sydney with PCL lawyers can help businesses trust and identify legal risks, clarify obligations and create a strategy... Read more

Writers Wanted



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion